Kura Oncology (NASDAQ:KURA) SVP Sells $60,421.32 in Stock

Kura Oncology, Inc. (NASDAQ:KURA) SVP Thomas James Doyle sold 7,142 shares of the company’s stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total transaction of $60,421.32. Following the completion of the transaction, the senior vice president owned 145,167 shares in the company, valued at $1,228,112.82. This represents a 4.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Thomas James Doyle also recently made the following trade(s):

• On Friday, November 14th, Thomas James Doyle sold 4,539 shares of Kura Oncology stock. The stock was sold at an average price of $11.18, for a total transaction of $50,746.02.

Kura Oncology Trading Down 1.2%

Shares of Kura Oncology stock traded down $0.10 on Tuesday, hitting $8.47. 1,149,028 shares of the company traded hands, compared to its average volume of 1,287,347. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 0.02. The company has a market cap of $737.06 million, a PE ratio of -3.42 and a beta of 0.25. The stock’s 50 day moving average price is $10.33 and its 200-day moving average price is $9.05. Kura Oncology, Inc. has a 52 week low of $5.41 and a 52 week high of $12.49.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.28). The firm had revenue of $20.75 million for the quarter, compared to analysts’ expectations of $17.48 million. Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%. Equities research analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Institutional Trading of Kura Oncology

A number of institutional investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Kura Oncology by 41.4% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 46,363 shares of the company’s stock worth $482,000 after buying an additional 13,579 shares during the last quarter. Merit Financial Group LLC boosted its stake in Kura Oncology by 124.0% in the fourth quarter. Merit Financial Group LLC now owns 22,499 shares of the company’s stock valued at $234,000 after acquiring an additional 12,454 shares in the last quarter. Xcel Wealth Management LLC grew its holdings in Kura Oncology by 16.2% in the fourth quarter. Xcel Wealth Management LLC now owns 118,846 shares of the company’s stock worth $1,235,000 after purchasing an additional 16,525 shares during the last quarter. CWM LLC grew its holdings in Kura Oncology by 32.3% in the fourth quarter. CWM LLC now owns 156,544 shares of the company’s stock worth $1,626,000 after purchasing an additional 38,181 shares during the last quarter. Finally, Flower City Capital increased its position in shares of Kura Oncology by 20.0% during the fourth quarter. Flower City Capital now owns 12,000 shares of the company’s stock worth $125,000 after purchasing an additional 2,000 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. UBS Group upped their price objective on shares of Kura Oncology from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, November 14th. HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Kura Oncology in a report on Tuesday, January 13th. Zacks Research cut shares of Kura Oncology from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 20th. Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a research note on Friday, December 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a research note on Thursday, January 22nd. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Kura Oncology has a consensus rating of “Moderate Buy” and an average price target of $28.00.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.